Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm

Naveen Pemmaraju, Nathaniel R. Wilson, Joseph D. Khoury, Nitin Jain, Naval Daver, Sherry Pierce, Elias Jabbour, Tapan Kadia, Courtney DiNardo, Guillermo Garcia-Manero, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood (2021) 138 (15): 1373–1377.

https://doi.org/10.1182/blood.2021011817

Published: 2021

Journal Articles

Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study

Blood (2019) 134 (Supplement_1): 256.

https://doi.org/10.1182/blood-2019-122124

Published: 2019

Journal Articles

Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL)

Blood (2019) 134 (Supplement_1): 322.

https://doi.org/10.1182/blood-2019-124590

Published: 2019

Journal Articles

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Blood (2018) 131 (11): 1248–1257.

https://doi.org/10.1182/blood-2017-07-798751

Published: 2018

Includes: Supplemental data

Journal Articles

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation

Blood (2017) 129 (22): 3031–3033.

https://doi.org/10.1182/blood-2017-02-766154

Published: 2017

Includes: Supplemental data

Journal Articles

Patient-Reported Outcomes and Patient-Performed Testing in Measuring Functional Impairment after Stem Cell Transplant in Patients with Multiple Myeloma

Nina Shah, MD, Sergio A. Giralt, MD, Qiuling Shi, PhD, Loretta A. Williams, PhD APRN, Qaiser Bashir, MD, Muzaffar Qazilbash, MD, Richard E. Champlin, MD, Charles S. Cleeland, PhD, Xin Shelley Wang, MD MPH

Blood (2016) 128 (22): 538.

https://doi.org/10.1182/blood.V128.22.538.538

Published: 2016

Journal Articles

Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years

Qaiser Bashir, MD, Mohammed El Shazly, Denái R. Milton, Krina Patel, MD, Nina Shah, MD, Yago Nieto, MD PhD, Partow Kebriaei, MD, Uday R. Popat, MD, Simrit Parmar, MD, Betul Oran, MD, Stefan O. Ciurea, MD, Chitra Hosing, MD, Hans Lee, MD, Elisabet E. Manasanch, MD, Robert Z. Orlowski, PhD, MD, Richard E. Champlin, MD, Muzaffar Qazilbash, MD

Blood (2016) 128 (22): 3453.

https://doi.org/10.1182/blood.V128.22.3453.3453

Published: 2016

Journal Articles

Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results

Nina Shah, MD, Peter F Thall, PhD, Denái R. Milton, Qaiser Bashir, MD, Simrit Parmar, MD, Pei Lin, MD, Partow Kebriaei, MD, Yago Nieto, MD PhD, Uday R. Popat, MD, Chitra Hosing, MD, Amanda Cornelison, Ruby Delgado, Elizabeth J. Shpall, MD, Robert Z. Orlowski, MD PhD, Richard E. Champlin, MD, Muzaffar Qazilbash, MD

Blood (2016) 128 (22): 2269.

https://doi.org/10.1182/blood.V128.22.2269.2269

Published: 2016

Journal Articles

Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 ( Does It Matter )?

Jin S. Im, MD PhD, Rima M Saliba, PhD, Susan C Abraham, MD, William Ross, MD, Gabriela Rondon, MD, Asif Rashid, MD, Elizabeth J. Shpall, MD, Uday R. Popat, MD, Muzaffar Qazilbash, MD, Chitra M. Hosing, MD, Betul Oran, MD, Nina Shah, MD, Richard E. Champlin, MD, Amin M. Alousi, MD

Blood (2015) 126 (23): 1933.

https://doi.org/10.1182/blood.V126.23.1933.1933

Published: 2015

Journal Articles

Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Catherine M Claussen, MS, Tammy Chuang, Jatin Shah, MD, Hans Lee, MD, Nina Shah, MD, Krina K Patel, Qaiser Bashir, MD, Simrit Parmar, MD, Sheeba Thomas, MD, Muzaffar Qazilbash, MD, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Donna Weber, MD, Robert Z. Orlowski, PhD, MD, Lei Feng, MS, Elisabet E. Manasanch, MD

Blood (2015) 126 (23): 5390.

https://doi.org/10.1182/blood.V126.23.5390.5390

Published: 2015

Journal Articles

Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience

Reshma Ramlal, MD, Sameh Gaballa, MD, Julianne Chen, Gabriela Rondon, MD, Betul Oran, MD, Sairah Ahmed, MD, Qaiser Bashir, MD, Katayoun Rezvani, MD, PhD, David Marin, MD, Amin M. Alousi, MD, Partow Kebriaei, MD, Muzaffar Qazilbash, MD, Chitra Hosing, MD, Uday R. Popat, MD, Elizabeth J Shpall, MD, Richard Champlin, MD, Stefan O. Ciurea, MD

Blood (2015) 126 (23): 3225.

https://doi.org/10.1182/blood.V126.23.3225.3225

Published: 2015

Journal Articles

Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma

Yago Nieto, MD, PhD, Benigno C. Valdez, PhD, Peter F Thall, PhD, Wei Wei, MS, Roy Jones, MD PhD, Chitra M. Hosing, MD, Sairah Ahmed, MD, Uday R. Popat, MD, Elizabeth J. Shpall, MD, Muzaffar Qazilbash, MD, Alison M Gulbis, Paolo Anderlini, MD, Nina Shah, MD, Qaiser Bashir, MD, Amin M. Alousi, MD, Yasuhiro Oki, MD, Fredrick B. Hagemeister, MD, Richard E. Champlin, MD, Borje S. Andersson, MD PhD

Blood (2015) 126 (23): 1992.

https://doi.org/10.1182/blood.V126.23.1992.1992

Published: 2015

Journal Articles

Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM

Blood (2015) 126 (23): 1980.

https://doi.org/10.1182/blood.V126.23.1980.1980

Published: 2015

Journal Articles

Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study

Blood (2015) 126 (23): 929.

https://doi.org/10.1182/blood.V126.23.929.929

Published: 2015

Journal Articles

Plasmablastic Lymphoma: 28 Patient Single Institution Experience

Krina Patel, MD, Lei Feng, M.S., Yasuhiro Oki, MD, Muzaffar Qazilbash, M.D., Tariq Muzzafar, MBBS, Donna M. Weber, M.D., Nathan Fowler, MD, Uday R Popat, MD, Sheeba K. Thomas, M.D., Michelle A. Fanale, MD, Yago Nieto, MD, PhD, Nina Shah, MD, Qaiser Bashir, MD, Fredrick B. Hagemeister, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 4310.

https://doi.org/10.1182/blood.V122.21.4310.4310

Published: 2013

Journal Articles

High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma

Yago Nieto, MD, PhD, Nina Shah, MD, Uday R Popat, MD, Roy B Jones, PhD MD, Qaiser Bashir, MD, Rolland Bassett, MS, Benigno C. Valdez, PhD, Borje S Andersson, MD, PhD, Simrit Parmar, MD, Robert Z. Orlowski, M.D., Ph.D, Jatin J. Shah, M.D., Sheeba K. Thomas, M.D., Michael Wang, M.D., Richard E Champlin, MD, Muzaffar Qazilbash, M.D.

Blood (2013) 122 (21): 3346.

https://doi.org/10.1182/blood.V122.21.3346.3346

Published: 2013

Journal Articles

Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant

Blood (2013) 122 (21): 2083.

https://doi.org/10.1182/blood.V122.21.2083.2083

Published: 2013

Journal Articles

Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Krina Patel, MD, Robert Z. Orlowski, M.D., Ph.D., Nina Shah, MD, Qaiser Bashir, Simrit Parmar, M.D., Yvonne T Dinh, Gabriela Rondon, MD, Sergio A Giralt, MD, Richard E. Champlin, Muzaffar Qazilbash, M.D.

Blood (2012) 120 (21): 3115.

https://doi.org/10.1182/blood.V120.21.3115.3115

Published: 2012

Journal Articles

High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up

Simrit Parmar, M.D., Joshua Howell, PharmD, Michael Wang, M.D., Mubeen A Khan, Qaiser Bashir, MD, Jatin J. Shah, M.D., Nina Shah, MD, Uday R. Popat, M.D., Sergio A Giralt, MD, Robert Z. Orlowski, M.D., Ph.D., Muzaffar Qazilbash, M.D.

Blood (2012) 120 (21): 750.

https://doi.org/10.1182/blood.V120.21.750.750

Published: 2012

NARROW

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm

Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study

Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL)

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation

Patient-Reported Outcomes and Patient-Performed Testing in Measuring Functional Impairment after Stem Cell Transplant in Patients with Multiple Myeloma

Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years

Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results

Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 ( Does It Matter )?

Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience

Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma

Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM

Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study

Plasmablastic Lymphoma: 28 Patient Single Institution Experience

High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma

Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant

Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only